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NMR spectroscopy as a novel approach to the monitoring of renal
transplant function. High field 'H NMR spectroscopy was used for the
rapid multicomponent analysis of low molecular wt compounds in urine
in order to investigate the patterns of metabolic changes associated with
early renal allograft dysfunction. Urine samples were collected daily for
14 days from 33 patients who underwent primary renal allograft
transplantation, and analyzed by 500 and/or 600 MHz 'H NMR spec-
troscopy. All patients received 20 mg prednisolone and 5 mg/kg b.d.
oral cyclosporin A (CsA) solution. In this study no patient showed
clinical or histopathological evidence of CsA nephrotoxicity. For each
patient the NMR-generated metabolite data were correlated with the
clinical observations, graft biopsy pathology, and data from conven-
tional laboratory techniques for assessing renal function. The NMR
spectra of urine from patients with immediate functioning grafts were
similar with respect to their patterns of amino acids, organic acids and
organic amines, whereas the patients with delayed or non-functioning
grafts showed significantly different metabolite excretion patterns. In
longitudinal studies on individual patients there were increased urinary
levels of trimethylamine-N-oxide (TMAO), dimethylamine (DMA),
lactate, acetate, succinate, glycine and alanine during episodes of graft
dysfunction. However, only the urinary concentration of TMAO was
statistically significantly higher (P < 0.025) in the urine collected from
patients during episodes of graft dysfunction (410 102 LM TMAO/mM
creatinine) than in patients with good graft function (91 18 M
TMAO/mM creatinine) or healthy control subjects (100 50 M
TMAO/mM creatinine). These findings suggest that graft dysfunction is
associated with damage to the renal medulla which causes the release of
TMAO into the urine from the damaged renal medullary cells. This
provides a possible novel urinary marker for post-transplant graft
dysfunction. This study shows that NMR spectroscopy of biofluids,
when used in combination with conventional laboratory techniques, is
a valuable aid to renal transplant monitoring.
In recent years high-resolution 'H NMR spectroscopy has
been established as a powerful technique to explore the bio-
chemical composition of biological fluids [1—5] and dynamic
inter-molecular interactions occurring within these fluids [6, 7].
An important analytical advantage of NMR spectroscopy is that
it provides a rapid, non-destructive probe of the biochemical
composition of low molecular wt compounds in small samples
of untreated biofluids [4]. In the clinical situation, NMR spec-
troscopy of urine and plasma can be applied to the study of
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biochemical lesions associated with disease processes, such as
diabetes mellitus and inborn errors of metabolism, and to
monitor changes in metabolite profiles that occur with therapy
[1, 3—5]. In situations where renal damage is present in humans
or animals the low molecular wt metabolite profile of the urine
is significantly altered, and this is closely reflected in the 'H
NMR spectral fingerprint [8—13]. Furthermore, the NMR spec-
trum of urine can give information on the site and mechanism of
renal damage in experimental animals [8, 11]. Computer pattern
recognition analysis of 'H NMR urinalysis data in a variety of
experimental toxicity states (renal and non-renal) has led to
novel NMR-based methods for classifying sites and mecha-
nisms of action of toxins in the rat [13]. The unique exploratory
nature of 1H NMR spectroscopy in biofluid biochemistry has
also led to the discovery of several novel markers of nephron
damage, for example, the abnormal excretion profiles of tn-
methylamine-N-oxide (TMAO), dimethylamine (DMA) and di-
methylglycine (DMG) following the experimental exposure to
renal medullary toxins [11]. In a clinical situation, elevated
levels of DMA and DMG were detected by NMR spectroscopy
in the urine of a patient with acute renal failure due to accidental
exposure to phenol [12]. TMAO and DMA have also been
identified by NMR methods as being present in abnormal
concentrations in the plasma of patients with chronic renal
failure [14, 15]. Given the power of 'H NMR urinalysis as a
technique for probing renal function it is logical to extend this
approach to the study of renal allograft function as this still
poses significant diagnostic problems, and the dynamic changes
in renal biochemistry following transplantation are poorly un-
derstood.
The abnormal urinary excretion of specific enzymes and
proteins as possible markers of renal allograft rejection has
been studied extensively [16—20]. These urinary parameters are,
however, relatively non-specific due to the presence of con-
founding factors such as hypertension and infection, and the
use of either azathioprine or cyclosponin A (CsA) immunosup-
pression. Currently, the assessment of renal graft dysfunction
following transplantation relies on the measurement of plasma
creatinine and the often inconclusive histological results of a
renal biopsy, an invasive procedure which poses a risk to the
transplant patient. As a result, the differential diagnosis of graft
failure is often based on an individual patient's response to
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N = 33
21—65 years (mean 47 years)
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Carcinoma
Dysplastic kidneys
Immediate functioning grafts
Delayed functioning grafts
Grafts showing evidence of dysfunction <14 days
therapy. In the present study we have used 'H NMR spectros-
copy to explore the changes in low molecular wt metabolites in
the urine of renal transplant patients to further the understand-
ing of the biochemical perturbations that accompany graft
dysfunction, and as a possible means of detecting novel mark-
ers of acute rejection.
Methods
Patients
Urine and blood samples were collected daily from 33 con-
secutively treated patients who underwent primary renal al-
lograft transplantation. Thirty-one patients received cadaveric
grafts and two patients received a kidney from live-related
donors. Patient data, including etiology of primary renal disease
are given in Table 1. Nineteen patients (57.6%) achieved
immediate graft function, as defined by a fall in plasma creati-
nine to 300 jsmollliter or less within three days of transplanta-
tion. Initially, immunosuppression consisted of a combination
of 20 mg prednisolone and 5 mg/kg b.d. oral cyclosporin A
(CsA) solution. The CsA dosage was adjusted to maintain
whole blood levels (measured by monoclonal specific RIA [21])
within a therapeutic window of 250 to 400 nglml during the
induction phase, reducing to a maintenance level of 100 to 200
ng/ml [22]. In this study no patients showed clinical or biopsy
evidence of CsA nephrotoxicity. During the 14 day study period
graft dysfunction was diagnosed in 24 (72.7%) patients. Acute
rejection episodes were treated with intravenous methylpred-
nisolone, I g given daily for three consecutive days. The
diagnosis of acute graft rejection was based on established
clinical and biochemical criteria, which included, primarily: (1)
an increase in plasma creatinine that was reversible following
methyiprednisolone anti-rejection therapy; and also (2) graft
tenderness, (3) pyrexia in the absence of systemic infection, (4)
a decrease in urine volume and (5) weight gain.
'H NMR urinalysis
A 3 ml volume from each patient's daily random urine
specimen was lyophilized and reconstituted in 0.75 ml of 2H20
containing 1 mg/mi of sodium-3-trimethylsilyl-[2,2,3 ,3-2H4]-1 -
propionate (TSP) as a chemical shift reference (b 0.0). NMR
measurements were made on JEOL GSX500 and Varian
VXR600 spectrometers operating at 500.13 MHz and 599.945
MHz 'H frequencies, respectively. Typically for each sample,
64 free induction decays (FID' s) were collected into 32768
computer points following 30° pulses and spectral widths of
6000 Hz (500 MHz measurements) or 8000 Hz (600 MHz
measurements). The data acquisition time per FID was 2.73s
and a further delay of 2.27s was added between pulses to permit
full T1 relaxation. The residual water signal was suppressed by
application of a gated secondary irradiation field (off during
acquisition) at the water resonance frequency. For some sam-
ples, broad resonances due to the presence of slow tumbling
macromolecules (such as albumin in proteinuric patients) were
eliminated using the Hahn spin-echo (HSE) pulse sequence:
D — {90° — — l80°, — — acquire FID]
where r has a value of 68 ms and a sequence delay time D of 3
s. This experiment results in the attenuation of signals from
macromolecules with short T2 relaxation times and also gives J
coupling-dependent phase modulation of signals from spin-spin
coupled protons such that, for r = 1/2 J, doublets and quartets
are phase-inverted with respect to singlets and triplets which
remain phased-upright [25]. Assignment of resonances was
made by consideration of chemical shifts relative to TSP,
spin- spin coupling patterns and the pH dependence of chemical
shifts. Confirmation of analyte identification was ultimately by
addition of the standard material to samples and re-measuring
spectra. All spectra were scaled to the same signal-to-noise
ratio so that resonance intensities were directly comparable
Ultrafiltration of urine samples
For some proteinuric samples, ultrafiltration of the sample,
using a 10 k Dalton Centrisart centrifugal ultrafilter (Sartorius
Ltd, Epsom, Surrey, UK), was employed, prior to lyophiliza-
tion, to selectively remove the interfering macromolecules.
Conventional clinical chemical analysis
Whole blood was obtained by venepuncture using lithium
heparinized vacutainer tubes. Plasma was separated by centrif-
ugation at 3000 rpm for 10 minutes. Renal function tests (plasma
creatinine, urea and electrolytes) were performed on a multi-
channel American Monitor Parallel analyzer (American Moni-
tor UK Ltd., Burgess Hill, Sussex, UK). Whole blood CsA
levels were measured by 1251 radioimmunoassay using the
monoclonal specific antibody [21, 221 (Incstar Corp, Stillwater,
Minnesota, USA). Analysis of the routine 24-hour urine collec-
tions provided data on urine volume, creatinine clearance and
daily protein excretion.
Results
Comparison of the 'H NMR spectra of urine from normal
subjects and transplant recipients
A typical partial 600 MHz 'H NMR spectrum of normal
human urine (aliphatic region of the spectrum shown only), with
expansion of the vertical scale, is shown in Figure 1. These
spectra are very complex with many signals being detected
within a few minutes of the total scanning time. The high
spectral information density from a wide range of chemical
classes of endogenous metabolites is apparent, and the high
Table 1. Summary of the clinical background of renal transplant
patients followed in the present studies
Patients
Age
Sex
Primary renal disease 8
7
6
2
2
N = 19
N = 14
N = 24
between patients.
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Fig. 1. Partial 600 MHz 'H spectrum of normal human urine, and vertical expansion, showing some assigned resonances in the aliphatic region
of the spectrum (chemical shift range 0.6—4.6). Abbreviations are: Ac, acetate; Acac, acetoacetate; Ala, alanine; Ch, choline; Cit, citrate; Cn,
creatinine; DHA, dihydroxyacetone; DMA, dimethylamine; DMG, dimethylglyine; Gly, glycine; lie, isoleucine; Lac, lactate; N-Ac, N-acetylated
glycoproteins; N-Me, N-methylated metabolites; 3-OHB, 3-hydroxybutyrate; 3-OHIV, 3-hydroxyisovalerate; TMA, trimethylamine; TMAO,
trimethylamine-N-oxide; Val, valine.
field spectrum of such urine samples therefore gives a 'snap-
shot' of information on the relative activities of many cellular
biochemical pathways. Most of the major resonances have been
assigned but many minor resonances from metabolites in low
concentrations still await assignment. Signal assignment strat-
egies for 'H NMR spectra of human and animal biofluid spectra
have been considered in our earlier work [1, 4, 9]. The 600MHz
'H NMR spectra are more revealing than the 500 MHz spectra
in terms of numbers of resolved signals due to improved
dispersion and higher sensitivity. However, 500 MHz 'H NMR
spectra have been acquired for most serially-collected samples
in this study, and in general 600 MHz 1H NMR spectra were
only collected on samples of special interest or unusually high
complexity.
The partial 500 MHz 'H NMR spectra of normal human urine
and those of urine collected from four patients on the third day
post-renal transplantation are shown in Figure 2. The NMR
spectra of the patients' urine are representative of the group
studied as a whole, and demonstrate the different NMR spectral
profiles observed with different types of graft function. A
typical partial 500 MHz 'H NMR spectrum of control human
urine (Fig. 2A) shows signals from the urinary metabolites that
are normally observed in the chemical shift range 6 0.2 to 4.6.
The strongest signals are from the N-CH3 and N-CH2 protons of
creatinine with lesser contributions from glycine, citrate, ala-
nine and lactate and N-methylated metabolites in the chemical
shift range 6 3.1 to 3.3. The 'H NMR spectra of the patients'
urine samples (Fig. 2 B-E) were significantly different to those
of normal controls and reflect each patients' post-operative
status at a particular time point (day 3 post-transplant). The 'H
NMR spectrum for patient (B), who had a plasma creatinine of
202 SM/liter, shows a pattern of endogenous metabolites that is
typical for a renal transplant patient with an uneventful post-
operative recovery. Compared to normal urine the noteable
differences are a low citrate concentration and a broad envelope
of resonances over most of the spectral width due to the
presence of high levels of protein (mainly albumin). The broad
singlet at 63.71 (labeled V) is a consistent finding in the urine of
CsA-treated renal transplant patients and has been provision-
ally identified as being from the glycol carrier (a polyoxyethy-
lated oleic glyceride, POG) used in the oral CsA drug formula-
tion [231 (see below). The spectrum for this patient's urine is
TMAO
DHA
Acac 3-OHIV
3-OHB
Val
lie
4'
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Fig. 2. Partial 500 MHz single pulse 'H NMR
spectra of normal human urine (A) and urine
collected from 4 patients on day 3 post-renal
transplantation showing: immediate
functioning graft (B), urinary tract infection(C), renal tubular ischemia (D) and non-
functioning graft (E). Abbreviations are: as
for Figure 1 with the addition of GLC,
glucose; myo-inos, myo-inositol; P,
acetaminophen (paracetamol) metabolites;
Pep, peptides; Suc, succinate; V, CsA drug
vehicle.
otherwise unremarkable. Patient (C), a live-related transplant
recipient, had good renal function with respect to conventional
clinical measurements (such as plasma creatinine of 89 tiM/liter)
but had a coliform urinary tract infection (UT!). The abnormal
elevation of alanine, glycine, lactate, acetate and succinate was
observed, but there was no evidence of glycosuria. These
findings are consistent with the presence of a urinary tract
infection [24]. However, the elevation in glycine and alanine
could also indicate the presence of a minor lesion in S3 (pars
recta) of the proximal tubule as this has been observed in
experimental animals treated with the proximal tubule S3 toxin
mercury II chloride [8]. Patient (D) had an immediate function-
ing graft, however, graft biopsy (performed on day 3, after urine
collection) showed histological evidence of renal tubular necro-
sis. Plasma creatinine was 293 p.M/liter. Elevated levels of the
medullary osmolytes dimethylamine (DMA) and myo-inositol,
in combination with glycosuria and aminoaciduria suggested
that there was both renal cortical and medullary damage.
Signals from the major metabolites of acetominophen (parace-
tamol) were also detected in the urine of this patient, these
having been assigned in earlier studies on normal volunteers [4].
The presence of proteins and peptides in the urine of renal
transplant patients result in the broad extensively overlapped
resonances which obscure signals from low molecular wt spe-
cies and make the single pulse spectrum difficult to interpret
(Fig. 2E). This can be a particular problem in the group of
patients with non-functioning grafts who frequently have gross
proteinuria and hematuria, as illustrated by the NMR spectrum
of urine from patient (E). The sharp resonances of the low
molecular wt components were in this case almost completely
obscured by the broad envelope of resonances from macromol-
ecules with slow-tumbling times in solution (that is, with short
T2 relaxation times).
Methods to aid simplication of 'H NMR spectra of
transplant patient urines containing high levels of protein
Many of the urine samples that were collected within a few
days of transplantation contained protein, as did those samples
from patients with severe graft malfunction (Fig. 2E). In such
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B
Fig. 3. Comparison of partial 600 MHz (A
and B) and 500 MHz (C) 'H NMR spectra of
urine from patient F with severe proteinuria
showing the single pulse experiment of
untreated urine (A) with the JO k dalton
ultrafi/trate of the same urine (B) and Hahn
spin-echo experiment of the untreated urine
(C). Abbreviations are: as for Figure 1 with
the addition of Gin, giutamine.
cases we utilized several simple methods for minimizing spec-
tral interference from the broad macromolecular signals. For
instance, the application of the HSE experiments and ultrafil-
tration of the sample provided two effective alternative means
of eliminating the broad macromolecular signals. The partial
600 MHz 'H NMR spectra of urine from patient F are shown in
Figure 3, and compare the single pulse experiment on untreated
urine (A) with that of the 10 k dalton ultrafiltrate of the same
urine (B) and the partial 500 MHz 'H NMR spin-echo experi-
ment (HSE) on the untreated urine (C). Patient (F) had a
TMAO
Cii
N-Ac
C
Ac
Lac
Lac
Cii
DMA
N-Ac Ac
.1.
A
4.5 4 3.5 3 2.f 2 1.5
8 ppm
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non-functioning graft due to acute allograft rejection with a
plasma creatmine of 641 mol/liter and was passing minimal
volumes of heavily blood-stained urine. Hemodialysis was
required for the first week post-transplantation. The single
pulse experiment on untreated urine (A) resulted in an NMR
spectrum of broad resonances, due to the presence of proteins,
that was dilhicult to interpret. Ultrafiltration of the urine (B) has
removed the protein fraction and the resonances of the previ-
ously obscured low molecular wt components such as DMA,
acetate, alanine and lactate are clearly visible. The HSE exper-
iment on untreated urine (C) has also resulted in the elimination
of the broad protein resonances, and interpretation of the
spectrum when compared to the single pulse spectrum (A) has
been simplified. The sharp resonances of acetate, DMA, TMAO
and creatinine are clearly observed, and although the doublets
of alanine, lactate and valine are phase-inverted, they remain
easily identifiable. The combination of ultrafiltration of the
sample with spectral-editing techniques, such as the spin-echo
experiment, ensures that maximum biochemical information is
obtained from such complex urine samples.
Longitudinal variations in the NMR spectral profiles of urine
following transplantation in relation to graft function
The time-course of urinary excretion of metabolites in indi-
vidual patients with different clinical courses of recovery was
followed using NMR spectroscopy, and the profiles related
retrospectively to the course of clinical events. For example,
the partial 500 MHz 'H NMR spectra of urine collected
sequentially from Patient D between 2 to 13 days post-trans-
plantation are shown in Figure 4 (not all spectra are shown).
The changes in the excretion pattern of endogenous metabolites
reflect the changes in patient status with time and are typical of
the NMR profiles of patients with a similar post-transplant
course. The 65-year-old male patient had an immediately func-
tioning graft, but post-transplant bleeding necessitated transfu-
sion with nine units of blood. Urine output was good but the fall
in the plasma creatinine was slow over the first few days. The
whole blood CsA levels were consistently <200 nglml (Fig. 5).
A renal graft biopsy was performed on day 3 post-transplant
and the histological findings showed the presence of ischemic
tubular damage. A repeat biopsy was performed on day 7 and
acute graft rejection was diagnosed. The patient was com-
menced on i.v. methylprednisolone for three days with a
subsequent fall in plasma creatinine. The partial 500 MHz 'H
NMR spectra of urine collected between days 2 to 5 (Fig. 4)
show that, in the immediate post-transplant period, the NMR
profiles of urine on each day were very similar. Compared to
normal human urine (Fig. 2A) the differences included a notable
glycosuria on days 2 and 3 (blood glucose was <8 mM/liter),
proteinuria and peptiduria and an increased excretion of DMA.
In addition, another renal medullary osmolyte, myo-inositol,
was also detected in the urine collected on day 3. A graft biopsy
was performed at this time-point, day 3, following urine collec-
tion. The absence of aminoaciduria and the slight increase in
lactate excretion alone suggested that the ischemic tubular
damage (histological evidence from graft biopsy) was minimal.
The broad singlet at 3 3.71 (Fig. 4, labeled V) was observed in
all urine samples from this patient and signals from acetamino-
phen (paracetamol) metabolites (6 2.1 to 2.3) were detected in
the urine collected on days 3 to 7. By the fifth day post-
transplantation the lactate and glucose levels had returned to
normal and the broad resonances from the macromolecules had
decreased in intensity. However, a rise in dimethyiglycine
(DMG) and TMAO levels were observed with subsequent
alteration in the ratio of TMAO to DMA (Fig. 4). The change in
the 'H NMR spectral profile was observed two days prior to a
second graft biopsy, performed on day 7, which showed his-
topathological evidence of acute graft rejection. Methyipred-
nisolone therapy was administered on days 7 to 9. The NMR
spectra of urine collected on days 5 to 7 showed a sixfold
increase in the urinary concentration of TMAO between day 5
(TMAO = 1.5 mM/liter) and day 7 (TMAO = 8.8 mM/liter),
which then declined following methyl prednisolone anti-rejec-
tion therapy (days 7 to 9). By the thirteenth day post-transplan-
tation the urinary metabolite profile as detected by NMR
spectroscopy was similar to that of a non-transplanted control
(Fig. 2A).
An important consideration in the analysis of urine samples
from renal transplant recipients is the contribution to the results
from urine that may be produced by the patients native kidneys.
To eliminate this effect we studied the urine profile of a 64-year-old
male patient who had had a bilateral nephrectomy for transi-
tional cell carcinoma three years prior to transplantation. The
graft was initially non-functioning and hemodialysis was re-
quired for 16 days post-transplant. The partial 500 MHz 'H
NMR spectra of the 10 k dalton urine ultrafiltrates for days 1 to
8 post-transplantation are shown in Figure 6. A graft biopsy was
not performed until day 9, confirming graft rejection, and i.v.
methyiprednisolone was commenced. The urinary metabolite
changes observed between days 1 and 8 therefore are not
related to the invasive nature of the graft biopsy (day 9) or as a
result of methyiprednisolone therapy (days 9 to 11). On day 1
post-transplant there were high concentrations of lactate, ace-
toacetate, hippurate and TMAO (Fig. 6). On day 2 post-
transplantation urinary lactate and hippurate excretion had
further increased. The NMR metabolite excretion profile al-
tered again on day 3, lactate excretion being reduced, and
acetate, creatine (singlet, 3 3.05) and DMA excretion being
substantially increased (Fig. 6). Enhanced excretion of acetate
and DMA have been observed in the urine of experimental
animals exposed to renal medullary toxins [11] and creatinuria
has been observed following parenchymal injury caused by
toxins such as cadmium chloride [26]. The calculated molar
ratio of DMA to TMAO (taking into account numbers of
protons contributing to each signal as well as peak intensity)
also altered with time from 0.16:1 (day 1) to 4.5:1 (day 2) to
2.25:1 (day 3) to 1.93:1 (day 6) to 1.83:1 (day 8). In the spectral
profiles measured on days 3, 6 and 8, urine samples had
increased in complexity but were very similar in metabolite
contributions (such as acetate and alanine lactate), suggesting a
stable biochemical profile of the kidney over that time course.
Days 3 to 8 urines also showed a contribution from another
resonance at 64.02; this is not yet assigned but may be a signal
from a glycine conjugate (at the carboxylic acid group) of the
drug cefotaxime which was commenced on day 2 post-trans-
plantation.
Quantitative investigation of urinary trimethylamine-N-oxide
excretion in renal transplant patients with dUferent levels of
renal function
To further investigate the significance of the apparent in-
crease in TMAO excretion in individual renal transplant recip-
ients with graft dysfunction, we compared the concentrations of
TMAO and other urinary metabolites (DMA, alanine, lactate,
glycine and hippurate) in the urine of two groups of transplant
patients, those with good graft function and those with graft
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dysfunction Urine samples were collected on day 7 post-
transplantation, the time point at which graft biopsy was
performed in the group of patients with graft dysfunction. All
urine samples were collected prior to graft biopsy and methyl-
Fig. 4. Partial 'H 500 MHz NMR profiles of
urine collected days 2—13 post-transplant from
patient D with ATN and acute graft rejection.
Graft biopsies were performed on days 3 and
7 and methylprednisolone therapy given days
7—9. Abbreviations are: as for Figure 1 with
the addition of Gin, giutamine; Hip,
hippurate.
prednisolone therapy. The first group (Group 1, N = 9) con-
sisted of patients with uncomplicated renal allograft function
and the second group (Group 2, N = 10) consisted of patients
with renal allograft dysfunction, of which acute graft rejection
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had been diagnosed in nine patients and acute tubular necrosis
(ATN) in one other. Urinary levels of the NMR detectable
metabolites were quantitated by comparison of peak height
measurements with that of the internal TSP standard of known
concentration, and results corrected for creatinine excretion
(Table 2). There was no significant difference in DMA, alanine,
lactate, glycine and hippurate excretion between the two groups
of patients. However, there was a statistically significantly
higher urinary excretion of TMAO (P < 0.025 by unpaired
Student's t-test) in the group of patients with graft dysfunction
when compared to the good graft function group. In addition,
urine samples were collected from a group of healthy, non-
transplanted, individuals (Group 3, N = 9) and the TMAO
excretion compared with the two transplant patient groups (Fig.
7). The graph shows that patients with good graft function were
similar to control (non-transplanted) individuals with respect to
TMAO excretion, whereas patients with graft dysfunction
generally had a higher TMAO excretion. There was still some
degree of overlap between the three groups indicating that
measurement of urinary TMAO on its own would not be a
reliable marker of graft dysfunction. We are currently investi-
gating the possibility that TMAO excretion may be useful as
part of a combination of urinary markers for graft dysfunction.
Identification of signals from the GsA carrier fromulation
Cremaphore. The presence of the broad singlet at h 3.71 which
was observed in the NMR spectra of urine from all CsA-treated
patients has also been observed in the urine of rats following
CsA administration [27]. Identification of this resonance was
previously elusive but has been suggested as being an endoge-
nous metabolite and potential marker of CsA nephrotoxicity
[27]. The presence of this signal in the urine of all the transplant
patients examined in this study virtually irrespective of graft
function indicates that this signal is likely to be associated with
the drug therapy rather than a marker of toxicity or rejection.
To identify the resonance we added a volume (10%) of the oral
CsA solution to normal human urine and observed the presence
of the broad singlet at h 3.71 (Vi) and two additional broad
resonances in the chemical shift range bO.8 to 1.4, (V2, V3), as
shown in Figure 8. The addition of cremophore EL (Sigma) to
2H20 produced a similar pattern (not shown). We have subse-
quently observed this resonance in the urine of a patient with
acute renal failure receiving vitamin supplementation dissolved
in a similar glycol carrier as CsA. We conclude that the
unidentified resonance is from the CsA vehicle, a polyoxyeth-
ylated oleic glyceride (POG) [23].
Discussion
The present studies have demonstrated that high resolution
'H NMR spectroscopy of urine can be used as a non-invasive
means of probing abnormal biochemical profiles following renal
transplantation which, in the future, may be a powerful aid to
diagnosis. 'H NMR spectroscopy of biofluids allows for mini-
mal inconvenience to the patient and is ideally suited to the
investigation of metabolic perturbations associated with disease
Fig. 5. Days 1—14 post-transplant plasma creatinine, whole blood CsA
and 24-hour urine volume measurements for patient D. Graft biopsies
were performed on days 3 and 7 and methyiprednisolone therapy given
days 7—9. Symbols are: (—0—) plasma creatinine; (*) CsA; () urine
volume,
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processes. We have shown that high resolution 'H NMR
spectroscopy can be used to monitor metabolite excretion
profiles which appear to parallel the graft function of patients
following renal transplantation. In the immediate post-trans-
plant phase all urine samples had varying degrees of NMR-
detectable proteinuria and peptiduria. In some cases, to maxi-
mize the biochemical information content of the spectra, careful
choice of sample preparation and NMR experimentation were
required (including choice of magnetic field strength) which can
also minimize the risk of spectral misinterpretation due to peak
overlap.
In patients with clinical evidence of renal ischemia and ATN
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Fig. 6. Partial 1H 500 MHzNMR spectra of
10 k dalton ultrafiltrates of urine collected
days 1—8 post-transplant from patient E with a
non-functioning graft. Abbreviations are in
Figs. 1 and 3 legends.
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Metabolite
/SM/mM creatinine
Group 1 (N = 9)
good graft function
Group 2 (N = 10)
graft dysfunction
TMAO 91 18 410 1o2
DMA 146 25 335 93
Alanine 181 51 224 107
Lactate 352 161 216 54
Glycine 770 180 623 233
Hippurate 55 13 123 40
the NMR spectra showed high levels of lactate, acetoacetate,
hippurate and acetate, but minimal aminoaciduria. The high
urinary levels of organic acids reflected the renal functional
impairment caused by ATN. In contrast, the patient with UTI
(Fig. 2C) and excellent renal function by conventional clinical
measurements, showed marked organic aciduria and aminoacid-
uria by NMR, and this was reduced following antibiotic therapy
(data not shown). These findings are probably consistent with
the presence of a bacterial infection [24]. The absence of
glycosuria in this patient also excludes significant proximal
tubular damage at that time point, although some low level of
damage to the pars recta (S3) of the proximal tubule could be
indicated by the elevated urinary glycine and alanine. In all
patients studied, the urinary levels of citrate were low in
comparison to normal, suggesting a concurrent renal tubular
acidosis.
The abnormal excretion of the renal medullary osmolytes
TMAO and DMA were associated with episodes of graft
dysfunction, in particular biopsy-confirmed acute graft rejec-
tion. High urinary levels of TMAO or DMA were not observed
in the group of patients with an uncomplicated post-transplant
course. TMAO and DMA are closely related to or, are derived
from, renal medullary organic osmolytes [28, 29], and previous
studies, using NMR spectroscopy in combination with other
analytical techniques, have identified certain osmolytes (nota-
bly TMAO, betaine, inositol, sorbitol and glycerophosphoro-
choline) in the rabbit and rat renal inner medulla [11, 28]. The
abnormal urinary excretion of TMAO and DMA by renal
transplant recipients with graft dysfunction is interesting in that
the experimental exposure to the renal papillary toxins 2-bro-
moethanamine and propyleneimine also results in a rise in the
urinary levels of TMAO and DMA [10, 11], suggesting that
elevated urinary levels of these compounds may be related to
leakage from damaged medullary cells. In the transplant situa-
tion, the significance of an increased excretion of TMAO has
yet to be clarified, and indeed it may be changes in the ratio of
one osmolyte to another, such as TMAO to DMA, that is more
diagnostically important. In the group of patients studied, a high
excretion of TMAO appears to be associated with biopsy-
confirmed acute graft rejection episodes; however, further
studies are required to confirm this finding. In particular, renal
medullary damage due to post-transplant renal reflux or sub-
clinical CsA toxicity needs investigation. These preliminary
results suggest, however, that TMAO may be important as a
novel marker of renal medullary damage in humans. The
regulation of osmolytes is considered to be multifactoral and
1 2 3
poses a complex problem when applied to human renal physi-
ology. In a clinical situation many factors have to be consid-
ered, including hydration of the patient, dietary intake, hor-
monal influence, dialysis therapy and the use of drugs,
particularly diuretics. An increased understanding of the me-
tabolism of the osmolytes in healthy individuals is clearly
required, and as a result we have initiated an investigation of
the normal physiological variance of endogenous metabolites
during differing degrees of stress in healthy individuals.
Finally, the positive identification of the vehicle of the oral
CsA formulation in the urine is important in that this previously
unassigned resonance has been considered as an endogenous
marker of CsA toxicity [26]. It has been reported that cremo-
phore EL, a polyoxyethylated castor oil used in the i.v. CsA
formulation, causes vasoconstriction in experimental toxicity
studies [30], however, very little has been published on the
potential side-effects of the polyoxyethylated vehicle of the oral
CsA solution. The significance of the appearance of this carrier
in the urine, and correlation with CsA toxic episodes, remains
to be determined, but 1H NMR spectroscopy appears to pro-
vide a rapid method of detecting the CsA carrier in the urine,
Table 2. 'H NMR detectable metabolite concentrations (sM/mM
creatinine) in the urine of two groups of renal transplant patients
collected on day 7 post-renal transplantation
Values are means SE.
P 0.025, significantly different to Group 1 (Student's unpaired
t-test)
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Fig. 7. Individual data-points for TMAO concentration (pM/mM creat-
mine) in urine samples collected on day 7 post-transplantation from:
Group 1, patients with good graft function (N = 9), Group 2, patients
with graft dysfunction (N = 10), and random urine samples from
normal, non-transplanted individuals, Group 3 (N = 9).
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Fig. 8. Partial 'H 500 MHz NMR ofnormal
human urine (A) and the same urine following
the addition of the 100 mg/mI oral GsA
solution (B). Abbreviations are: Vi, V2, V3
CsA drug vehicle.
which may be useful in subsequent studies of its excretion and
potential toxicity.
The application of 'H NMR spectroscopy of urine to monitor
the biochemical and functional integrity of renal allograft func-
tion has revealed that, in the early phase post-transplantation,
the abnormal urinary excretion of endogenous low molecular wt
metabolites appears to correlate with episodes of graft dysfunc-
tion. The routine biochemical profiles obtained by clinical
chemical analysis provide information on renal function alone,
with very little information given on the site and severity of a
lesion, and therefore do not distinguish between the different
causes of graft dysfunction. An early differential diagnosis is
vital, however, in order to initiate early intervention therapy
and improve graft outcome. 'H NMR spectroscopy provides
unique biochemical information that is not available with any
other single analytical technique, and the present study high-
lights the important contribution of 'H NMR spectroscopy to
the investigation of metabolic perturbations following renal
transplantation. The long-term follow-up of these patients will
enable us to study chronic graft rejection, CsA associated
toxicity and, in some cases, return of the primary disease.
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